Discover open access scientific publications

Search, annotate, share and cite publications

Publications by I. Flinn

Augment: Relapsed/Refractory Indolent NHL Patients Were More Sensitive to Next Treatment Following Lenalidomide/Rituximab (R2 ) Than Rituximab/Placebo

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Augment Phase Iii Study: Lenalidomide/Rituximab (R2 ) Improved Efficacy Over Rituximab/Placebo in Relapsed/Refractory Follicular Patients Irrespective of Pod24 Status

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Post Hoc Analyses of Patients With Relapsed/Refractory Marginal Zone Lymphoma Who Received Lenalidomide Plus Rituximab (R2 ) vs Rituximab/Placebo (Augment)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Patterns of Duvelisib-Induced Lymphocytosis in Patients With R/R CLL or SLL Including Those With High-Risk Factors Treated in the Duo Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

First-Line Treatment of Inhl or MCL Patients With Br or R-Chop/R-Cvp: Results of the Bright 5-Year Follow-Up Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT-NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy